The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer

Background The use of immune checkpoint inhibitors (ICIs) as first‐line treatment rather than as second‐line treatment makes a big difference in the drug efficacy and progression‐free survival. However, the mechanism for this is still not clear. This study aimed to analyze the effects of the rest pe...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2022-08, Vol.13 (16), p.2346-2354
Main Authors: Kang, Da Hyun, Choi, Seong‐woo, Sun, Pureum, Chung, Chaeuk, Park, Dongil, Lee, Song‐I, Koh, Jeong Suk, Kim, Yoonjoo, Lee, Jeong Eun
Format: Article
Language:English
Subjects:
Apoptosis
Blood
Cancer therapies
Chemotherapy
Cytotoxicity
Drug efficacy
Flow cytometry
Immunotherapy
Ligands
Lung cancer
Medical prognosis
Neutrophils
Original
Patients
PD‐1/PD‐L1 inhibitor
Software
time interval
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The use of immune checkpoint inhibitors (ICIs) as first‐line treatment rather than as second‐line treatment makes a big difference in the drug efficacy and progression‐free survival. However, the mechanism for this is still not clear. This study aimed to analyze the effects of the rest period between chemotherapy and immunotherapy on the efficacy of ICIs. Methods This study included 100 patients with advanced NSCLC treated with PD‐1/PD‐L1 inhibitors at Chungnam National University Hospital (CNUH) between May 2016 and August 2019. The rest period was defined from the last dose of cytotoxic chemotherapy to the first dose of ICIs. We retrospectively reviewed patients' clinical data and blood test records and analyzed lymphocyte subsets using flow cytometry. Results The median rest period was 64 days. The long rest period group (≥36 days) showed significantly higher clinical benefits than the short rest period group (
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.14568